Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Peroxisome proliferator-activated receptor gamma (PPARγ) is implicated as an oncogene in prostate cancer (PC) progression.
• PPARγ antagonists have demonstrated efficacy in inhibiting PC cell proliferation.

Purpose of the Study:

• To identify novel chemotypes of PPARγ antagonists using a virtual screening approach.
• To investigate potential binding sites and key residues for PPARγ antagonist interaction.

Main Methods:

• Utilized virtual screening to identify potential PPARγ antagonist compounds.
• Focused screening on the allosteric pocket of PPARγ.

Main Results:

• Discovered novel chemotypes acting as PPARγ antagonists.
• Identified specific amino acid residues (Arg288, Lys367, His449) crucial for antagonist binding.
• The identified compounds bind to an allosteric site on PPARγ.

Conclusions:

• Virtual screening is effective for discovering novel PPARγ antagonists.
• Targeting the allosteric pocket of PPARγ offers a promising strategy for prostate cancer therapy.
• Specific residues like Arg288, Lys367, and His449 are key for designing effective PPARγ antagonists.